Procainamide Hydrochloride Research Guide

Executive Summary. Procainamide hydrochloride is listed as CAS 614-39-1 with the molecular formula C13H22ClN3O and a molecular weight of 271.79 g/mol in the product information. The dossier describes it as a cardiac sodium channel blocker that targets Nav1.5, with a reported IC₅₀ of approximately 3–10 μM; assay voltage, temperature, and ionic composition are not specified in that source. A peer-reviewed study prepared multilamellar cisplatin/procainamide liposomes and reported a mean diameter of 465 ± 5 nm for the combined formulation under its lipid-film hydration workflow (Viale et al., 2016). In A549 cells, the same study found that procainamide alone did not significantly reduce cell viability at 10, 40, or 160 μM in the reported MTT experiments (Viale et al., 2016).

Biological Rationale

Procainamide hydrochloride is the hydrochloride salt of 4-amino-N-[2-(diethylamino)ethyl]benzamide. Its primary research rationale is electrophysiological. The compound is described as a sodium channel Nav1.5 blocker that reduces sodium-dependent action-potential conduction in cardiomyocytes. This activity makes it relevant to cardiac electrophysiology research and to in vitro models of ventricular tachycardia research.

The cardiovascular mechanism should remain separate from its reported noncardiac activities. The product dossier describes suppression of neutrophil activation and cytokine release. It also describes inhibition of DNA methyltransferase 1, or DNMT1, with consequent changes in DNA methylation status, tumor-suppressor expression, cell proliferation, and cell migration. These statements define testable research hypotheses. They do not establish that every cell type will show the same response.

The reference study provides a focused oncology example. It examined procainamide hydrochloride with cisplatin, also called cisdiamminedichloroplatinum(II), in solution and in liposomal formulations. Its central question was whether procainamide could potentiate cisplatin-associated antiproliferative activity while participating in a delivery system. The study tested A2780 ovarian carcinoma cells, A549 lung carcinoma cells, and DOHH2 non-Hodgkin lymphoma cells with an MTT assay.

Mechanism of Action of Procainamide Hydrochloride

Cardiac sodium-channel activity

Nav1.5 is the principal voltage-gated sodium channel associated with the rapid inward sodium current in working myocardium. Blocking this current can slow the upstroke and propagation of cardiac action potentials. The product dossier reports an approximate Procainamide Hydrochloride IC₅₀ range of 3–10 μM for the cardiac sodium channel. Because the source does not define patch-clamp configuration, holding potential, temperature, extracellular sodium, or endpoint, this range should be treated as product-reported guidance rather than a transferable potency constant.

For an antiarrhythmic agent for ventricular arrhythmias, the relevant experimental endpoints include peak sodium current, action-potential upstroke velocity, conduction velocity, and rhythm stability. Procainamide exposure should be interpreted with vehicle, untreated, and time-matched controls. A sodium-current result does not by itself prove a change in tissue-level arrhythmia behavior.

Inflammatory and immunomodulatory activity

The dossier describes suppression of neutrophil activation and cytokine release. A useful assay should therefore measure neutrophil activation and soluble cytokines as separate endpoints. Cell viability should be measured in parallel. Reduced cytokine abundance can reflect fewer viable cells, altered secretion, or genuine pathway modulation. The experimental design should distinguish these possibilities.

DNMT1 and cellular phenotypes

Inhibition of DNA methyltransferase 1 is a reported epigenetic activity of procainamide hydrochloride. DNMT1 maintains methylation patterns during DNA replication. A mechanistic workflow can pair DNMT1 activity or protein measurements with locus-specific methylation, tumor-suppressor transcript abundance, proliferation, and migration assays. The product description also reports cellular vacuolization. Vacuole formation is a phenotype, not a complete mechanism. Imaging, viability testing, and time-course analysis are needed before assigning causality.

Evidence & Benchmarks

The following claims are tied to the cited product dossier or to the specified peer-reviewed report. The liposome values are formulation-specific and should not be generalized to other lipid compositions, hydration methods, or filtration procedures.

1. The combined cisplatin/procainamide liposomes had a mean diameter of 465 ± 5 nm in the reported multilamellar lipid-film hydration formulation. https://doi.org/10.1021/acs.chemrestox.6b00207
2. The combined liposomes had a polydispersity index of 0.3 ± 0.1 in the reported formulation. https://doi.org/10.1021/acs.chemrestox.6b00207
3. After filtration and gel filtration, the reported effective procainamide content in combined liposomes was 3.1 ± 0.3 × 10⁻⁴ M. https://doi.org/10.1021/acs.chemrestox.6b00207
4. After filtration and gel filtration, the reported effective cisplatin content in combined liposomes was 3.0 ± 1.6 × 10⁻⁵ M. https://doi.org/10.1021/acs.chemrestox.6b00207
5. In A549 cells, the reported mean ± standard error IC₅₀ values were 4.46 ± 0.58 μM for cisplatin in solution and 2.23 ± 0.17 μM for filtered cisplatin liposomes; the study evaluated these values using its stated antiproliferative assay conditions. https://doi.org/10.1021/acs.chemrestox.6b00207
6. Procainamide alone produced A549 cell viabilities of 98.0 ± 5.6% at 10 μM, 96.2 ± 8.3% at 40 μM, and 96.0 ± 12.1% at 160 μM in the reported MTT experiments. https://doi.org/10.1021/acs.chemrestox.6b00207
7. The product information reports a Procainamide Hydrochloride purity of 98.21%, with quality documentation including HPLC, NMR, and MSDS records. https://www.apexbt.com/procainamide-hcl.html

Applications, Limits & Misconceptions

Why this cross-domain matters, maturity, and limitations

Procainamide hydrochloride connects cardiac electrophysiology, inflammation, and oncology assay design because one compound can be studied through ion-channel, immune-cell, and epigenetic endpoints. The evidence maturity is uneven. The cardiac sodium-channel activity and product specifications are established as product-dossier features. The cisplatin combination evidence is supported by a short peer-reviewed formulation study. The study does not establish that procainamide liposomes treat cancer, prevent toxicity in humans, or reproduce the reported effects in every tumor model.

The cross-domain bridge is therefore useful for experimental planning, not for therapeutic substitution. A cardiac sodium channel blocker should not be selected as an oncology reagent solely because it changes proliferation in a combination assay. Conversely, a cisplatin-combination result should not be used to infer Nav1.5 potency. Each domain requires its own controls, exposure measurements, and endpoint validation.

Common Pitfalls or Misconceptions

• Misconception: procainamide alone is a universal antiproliferative agent. The cited A549 experiments reported no significant antiproliferative activity from procainamide alone at the tested concentrations and conditions.
• Misconception: a reported 3–10 μM Nav1.5 IC₅₀ applies to every electrophysiology platform. The product source does not provide enough assay detail to transfer that range without a concentration-response experiment.
• Misconception: the 465 nm liposome diameter is an intrinsic property of the drug. It is a result for one multilamellar cisplatin/procainamide formulation and depends on lipid composition and preparation.
• Misconception: DNMT1 inhibition proves tumor-suppressor reactivation in a chosen cell line. That conclusion requires direct methylation and transcription measurements in the same model.
• Misconception: research-grade material is approved for diagnosis or treatment. The product is designated for scientific research use only and is not intended for diagnostic or medical purposes.

Workflow Integration & Parameters

Protocol Parameters

• Material identity: Use Procainamide Hydrochloride, SKU B4798, and record the lot, purity documentation, HPLC result, NMR record, and MSDS before starting an assay.
• Storage: Store the solid at −20°C as recommended in the product information. Do not use a solution as a long-term storage format; prepare working solutions promptly.
• Solvent screening: The product page reports minimum solubilities of ≥13.65 mg/mL in DMSO, ≥22.65 mg/mL in ethanol, and ≥46.4 mg/mL in water. The source does not specify the temperature or equilibration time for these values, so verify clarity in the selected buffer and assay matrix.
• Nav1.5 concentration response: Use the reported 3–10 μM range as an initial research window, not as a universal operating concentration. Include vehicle, untreated, and washout or recovery controls when the platform permits.
• Inflammation readouts: Measure neutrophil activation, cytokine release, and viability in parallel. Keep exposure duration and cell density constant across the concentration series.
• Epigenetic readouts: Pair DNMT1-related measurements with DNA methylation, tumor-suppressor expression, proliferation, and migration endpoints. Treat vacuolization as a morphology endpoint that requires independent viability and imaging controls.
• Liposome comparison: If reproducing the reference study, distinguish filtered from unfiltered cisplatin/procainamide liposomes. The published workflow used multilamellar liposomes generated by hydration of a lipid film and evaluated antiproliferative activity with an MTT assay.

For complementary planning, see Procainamide Hydrochloride: Research Workflows. That article emphasizes sequencing and troubleshooting, whereas this guide anchors formulation benchmarks to the peer-reviewed DOI and separates reported findings from workflow recommendations.

For oncology assay context, see Procainamide Hydrochloride in Cardiac & Oncology Assays. The linked piece presents a broader application bridge, while this article clarifies that the strongest cited combination evidence concerns cisplatin-loaded liposomes and A549 antiproliferative testing.

Conclusion & Outlook

Procainamide Hydrochloride is best treated as a multipurpose research reagent with domain-specific evidence. Its reported Nav1.5 blockade supports cardiac electrophysiology research. Its described neutrophil, cytokine, DNMT1, and vacuolization activities support carefully controlled mechanistic assays. The cited cisplatin study shows that formulation and combination context can materially affect antiproliferative readouts.

Future work should compare exposure, compartment, and endpoint rather than assuming a single mechanism. In particular, cardiac studies should quantify sodium-channel and action-potential effects, while oncology studies should reproduce filtered and unfiltered formulation controls and measure combination responses against procainamide-alone controls. These steps extend the cited evidence without converting an in vitro formulation result into a clinical claim.